TCR Specifically Recognizing Prame Antigen, and Co-Expressing Same with CD8 for Redirecting CD4 T Cells
AssigneeNeowise Biotechnology Co., Ltd.
InventorsSongming PENG, Duo AN, Shan ZHONG
Life of this patent
Estimating the term…
Abstract
Provided are a T cell receptor (TCR) that specifically binds to a PRAME antigenic short peptide, a fusion protein or a conjugate comprising the TCR, a nucleic acid encoding the TCR, an engineered cell comprising the same, and a method for preparing the engineered cell. Co-expressing an exogenous CD8 molecule and the TCR gene in a T cell can enhance the functions of the T cell. Further provided is the use of the TCR and the genetically engineered cell in the detection, prevention and/or treatment of PRAME-associated diseases (e.g., PRAME-associated cancers).
Claims13
An isolated or purified T-cell receptor (also abbreviated as TCR), characterized in that the TCR binds specifically to PRAME antigenic short peptide, and comprises an α chain and a β chain, wherein each of the α chain and β chain comprises three complementarity determining regions (also abbreviated as CDRs), and wherein the amino acid sequence of CDR3 of the α chain is selected from SEQ ID NOs:
- 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, and a variant having one or two amino acid residue changes from the sequence, and the amino acid sequence of CDR3 of the β chain is selected from SEQ ID NOs:
- 269, 272, 275, 278, 281, 284, 287, 290, 293, 296, 299, 302, 305, 308, 311, 314, 317, 320, 323, 326, 329, 332, 335, 338, 341, 344, 347, 350, 353, 356, 359, 362, 365, 368, 371, 374, 377, 380, and a variant having one or two amino acid residue changes from the sequence.
Dependencies are inferred from the claim text.